caa a22 4500 606220666 CHVBK 20210128101125.0 cr unu---uuuuu 210128e20151101xx s 000 0 eng 10.1007/s00380-014-0544-1 doi (NATIONALLICENCE)springer-10.1007/s00380-014-0544-1 Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension [Elektronische Daten] [Masaru Hatano, Hidehiro Yamada, Keiichi Fukuda, Koichiro Yoshioka, Masanori Funauchi, Masataka Kuwana, Masataka Sata, Mitsugu Taniguchi, Norifumi Nakanishi, Takefumi Saito, Tsutomu Saji, Shigetake Sasayama] Pulmonary arterial hypertension (PAH) trial has mostly enrolled patients with World Health Organization functional class (WHO FC) III or IV. However, PAH is rapidly progressive in nature even in patients with less severe forms at diagnosis. Following the recent studies in Western population, here we assessed the efficacy of bosentan in Japanese patients with WHO FCII PAH. In this open-label trial, bosentan 125mg twice daily was administered for 12weeks in 16 patients, and a hemodynamic evaluation was performed. Treatment was continued for a further 12weeks, where the effect on exercise capacity was assessed in 13 patients. In 16 patients, mean pulmonary arterial pressure decreased from 40.4±10.4 to 35.6±12.6mmHg (p=0.018) and cardiac index increased from 2.54±0.73 to 2.96±0.82L/min/m2 (p=0.023). Thus, pulmonary vascular resistance decreased from 792±565 to 598±558 dyn·sec/cm5 (p=0.006). In 13 patients followed up for 24weeks, 6-min walking distance increased from baseline at Week 12 (p=0.003) and Week 24 (p=0.011). All patients were mildly symptomatic at baseline with dyspnea index (Borg scale) of 2.50±1.58 and the specific activity scale (SAS) of 5.0±1.4 METs. These values remained unchanged throughout the study. These results suggest that bosentan treatment was beneficial for Japanese patients with WHO FC II PAH and treatment should be started in the early stage of the disease. Springer Japan, 2014 Bosentan nationallicence Endothelin receptor antagonist nationallicence Pulmonary arterial hypertension nationallicence Hemodynamics nationallicence World Health Organization functional class nationallicence Hatano Masaru Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan aut Yamada Hidehiro Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan aut Fukuda Keiichi Department of Cardiology, Keio University School of Medicine, Tokyo, Japan aut Yoshioka Koichiro Department of Cardiovascular Medicine, Tokai University School of Medicine, Kanagawa, Japan aut Funauchi Masanori Department of Hematology and Rheumatology, Kinki University Faculty of Medicine, Osaka, Japan aut Kuwana Masataka Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan aut Sata Masataka Department of Cardiovascular Medicine, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan aut Taniguchi Mitsugu Division of Cardiology, Kinki University Faculty of Medicine, Osaka, Japan aut Nakanishi Norifumi Division of Pulmonary Circulation, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan aut Saito Takefumi Department of Respiratory Medicine, National Hospital Organization Ibaraki-Higashi National Hospital, Ibaraki, Japan aut Saji Tsutomu Department of Pediatrics, Toho University Omori Medical Center, Tokyo, Japan aut Sasayama Shigetake Kyoto University, Kyoto, Japan aut Heart and Vessels Springer Japan 30/6(2015-11-01), 798-804 0910-8327 30:6<798 2015 30 380 https://doi.org/10.1007/s00380-014-0544-1 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00380-014-0544-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hatano Masaru Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan aut NATIONALLICENCE 700 1- Yamada Hidehiro Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan aut NATIONALLICENCE 700 1- Fukuda Keiichi Department of Cardiology, Keio University School of Medicine, Tokyo, Japan aut NATIONALLICENCE 700 1- Yoshioka Koichiro Department of Cardiovascular Medicine, Tokai University School of Medicine, Kanagawa, Japan aut NATIONALLICENCE 700 1- Funauchi Masanori Department of Hematology and Rheumatology, Kinki University Faculty of Medicine, Osaka, Japan aut NATIONALLICENCE 700 1- Kuwana Masataka Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan aut NATIONALLICENCE 700 1- Sata Masataka Department of Cardiovascular Medicine, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan aut NATIONALLICENCE 700 1- Taniguchi Mitsugu Division of Cardiology, Kinki University Faculty of Medicine, Osaka, Japan aut NATIONALLICENCE 700 1- Nakanishi Norifumi Division of Pulmonary Circulation, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan aut NATIONALLICENCE 700 1- Saito Takefumi Department of Respiratory Medicine, National Hospital Organization Ibaraki-Higashi National Hospital, Ibaraki, Japan aut NATIONALLICENCE 700 1- Saji Tsutomu Department of Pediatrics, Toho University Omori Medical Center, Tokyo, Japan aut NATIONALLICENCE 700 1- Sasayama Shigetake Kyoto University, Kyoto, Japan aut NATIONALLICENCE 773 0- Heart and Vessels Springer Japan 30/6(2015-11-01), 798-804 0910-8327 30:6<798 2015 30 380